Over 20 years, Unitaid has helped expand access to 150+ health innovations reaching 320M+ people annually.
But innovation only matters when it reaches those who need it most. Impact depends on delivery, affordability, and scale.
When health product markets are disrupted, access is disrupted.
2025 data shows:
• 42% fewer people started oral HIV prevention
• 5.8M fewer HIV tests
• 39K fewer adults started treatment
• 26K fewer children on treatment
Protecting progress means protecting access.
“The current conflict is a reminder that access to health products depends on resilient systems.”
Innovation alone isn’t enough. Health supply chains must withstand climate and conflict shocks through low-carbon, resilient systems.
The Lancet
Asian Development Bank
Health Care Without Harm Europe
For 20 years, we have worked to expand access to health innovations at scale.
Our work addresses barriers that slow or limit access, affordability, supply, and delivery.
This has supported faster introduction and wider reach.
Access is what determines impact.
For 20 years, we have worked to bridge the gap between innovation and access in global health.
Innovation only matters when it reaches the people who need it.
Video
Unitaid
Unitaid
Unitaid
Unitaid
What if one of the greatest opportunities to improve child health isn't a new innovation, but better delivery of existing ones?
Our latest blog explores how pulse oximetry can turn innovation into impact through stronger delivery systems, oxygen access and routine use in care.
Unitaid
Lenacapavir expands options for HIV prevention, but options only matter if people can access them.
South Africa’s rollout is an important step forward. Unitaid and partners are working to ensure this innovation reaches the people who need it most.
Access to health products depends on markets that work for the people who need them.
That means improving affordability, strengthening supply, and cutting delays that slow access to medicines and tools.
From pricing to delivery, the aim is turning innovation into impact.
Extreme heat can degrade medicines, reduce their potency and compromise care before they reach patients. Climate-resilient, heat-stable products are essential to protect health.
Learn more: https://ow.ly/wHye50YNubW
Lenacapavir is a long-acting HIV prevention option given as just two injections a year.
It adds to daily PrEP medication, which can be difficult to maintain due to stigma, access, or adherence challenges.
A 2025 partnership is helping turn this innovation into access across 120 countries.
